According to Future Market Insights (FMI) analysis in a recent market survey, the global cervical cancer screening market was valued at USD 1.4 Billion in 2022 and is expected to reach USD 5.7 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 1.4 Billion |
| Market Value 2023 | USD 1.6 Billion |
| Market Value 2033 | USD 5.7 Billion |
| CAGR 2023 to 2033 | 13.7% |
| Share of Top 5 Countries | 50.2% |
| Key Players | The key players in the cervical cancer screening market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche, Hologic, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Promega Corporation, Sysmex Inostics Inc., Danaher (Cepheid), FUJIREBIO, Everlywell, Inc., and Sansure Biotech Inc. |
Cervical screening encompasses various methods such as cervical cytology (Pap test or Pap smear), human papillomavirus (HPV) testing, or a combination of both. It is recommended that most women undergo routine cervical cancer screening to ensure early detection and appropriate preventive measures. A Pap test can occasionally reveal diseases like inflammation or infection that are not malignancy. The HPV/Pap co-test examines cervical cell alterations as well as high-risk HPV using both an HPV test and a Pap test.
Overall, the increasing screening for the detection of cervical cancer will boost the market in the coming years.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Sales of the cervical cancer screening market grew at a CAGR of 7.4% from 2012 to 2022. The cervical cancer screening market contributes a 0.7% revenue share to the global cancer diagnostics market in 2022 which was valued at USD 191.0 Billion.
About 70% of cervical cancer occurrences globally are caused by HPV strains 16 and 18. It is now possible to prevent HPV 16 and 18 infections, which has the potential to lower the prevalence of anogenital and cervical malignancies. Squamous intraepithelial lesion (SIL) and cervical intraepithelial neoplasia (CIN) are widely used terms to describe the presence of abnormal squamous cell growth in the cervix, indicating a precancerous condition.
On 4th March 2023, International Agency for Research on Cancer mentioned that more than 300 000 women per year die from cervical cancer, which is currently the fourth most prevalent cancer in women. In low- and middle-income nations, cervical cancer fatalities account for almost 90% of all deaths.
Other than the Pap test and HPV test, in low-resource situations, visual examination with acetic acid (VIA) can replace cytology-based screening.
Considering this, FMI expects the global cervical cancer screening market to grow at a CAGR of 13.7% through the forecasted years.
The objective of cervical cancer screening is to identify precancerous changes in cervical cells that can be effectively treated to prevent the progression of cervical cancer.
New advancements in human papillomavirus (HPV) DNA testing, Papanicolaou test technology, and updates to the Bethesda terminology for cervical cytology have led to changes in the management of abnormal Pap tests. A recent clinical trial has provided information that includes a reduction in the number of colposcopies required by 50% in certain cases. Femtech is driving a significant transformation in women's healthcare.
Leading manufacturers are focusing on affordable testing and also reducing the overall cost of treatment with the help of technologically advanced screening tests. This creates an opportunity for the market to expand exponentially.
The Pap test is a crucial element of a woman's overall health. It assists in the early detection of cervix precancerous cells before they transform into malignant cells. However, the Pap test has some limitations as a cervical cancer prevention method.
Traditional cervical cancer screening methods primarily focus on examining the end cervical canal. Patients often undergo an invasive procedure called a colposcopy when an abnormal Pap screening is observed. This involves visualizing cervical cancer and collecting tissue samples. However, for many years, the only available instruments for tissue collection were conventional ones such as brushes or a Kevorkian curette.
The Pap test's primary flaw is that, like many other tests, it is unable to provide accurate results. In the event that a Pap test yields a false positive result, the cervix may contain precancerous cells.
The USA dominated the global market with a value share of around 25.1% in 2022.
The American College of Obstetricians and Gynecologists (ACOG), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the Society of Gynecologic Oncologists SGO nonetheless advise starting cervical cancer screening at age 21. Obstetricians-gynecologists and other healthcare practitioners should continue to strongly advise eligible people to get the HPV vaccine and emphasize its advantages and safety as another key method of preventing cervical cancer.
The demand for cervical cancer screening will increase with the assistance of awareness created by the established player and create an area for diagnostics testing labs to provide low-cost health checkups, which will drive the expansion of the market.
Japan is projected to be the most attractive market in cervical cancer screening and holds a market share of 7.6% in the global market in 2022. The Japanese government is working actively for the benefit of women’s welfare.
Germany dominated the global market for cervical cancer screening and accounted for 6.3% of the market share in 2022.
Germany conducted a screening program for the prevention of cervical cancer in women from the age of 35 years with the collaboration of Statutory Health Insurance (GKV) to understand the dynamics of cervical cancer screening. A groundbreaking implementation of HPV co-testing and cytology in a substantial population of women aged 35 and above in Germany suggests that this approach could enhance cervical cancer prevention, particularly when combined with liquid-based computer-assisted cytology examinations that incorporate patients' HPV status.
The presence of prominent players in Germany will influence the overall market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The human papillomavirus (HPV) segment held the major chunk of 75.0% of the global market by the end of 2022.
The main factor causing cervical cancer is HPV. The majority of occurrences of cervical cancer are caused by high-risk HPV strains like HPV 16 and 18, which account for about 70% of cases, as per WHO 2022 insights.
Overall, human papillomavirus (HPV) is a widely adopted test that helps in screening for cervical cancer.
Squamous cell carcinomas were the predominant segment with a market share of 57.5% in the global market by the end of 2022.
As per the Cancer Research UK 2020 statistics, nearly 70% to 90% of all occurrences of cervical cancer are squamous cell carcinoma, making it the most prevalent kind. The squamous cells that border the outside of the cervix give rise to this type of cancer.
As it is the predominant occurring cervical cancer it holds the highest market share in the global market.
The 31 - 65 years age group accounted for a revenue share of 61.7% in the global market at the end of 2022.
The human papillomavirus (HPV), particularly HPV types 16 and 18 often acquired during sexual activity. The virus is often cleared by the immune system within a couple of years, but occasionally the infection lingers and raises the risk of cervical cancer.
Between the ages of 31 and 65, those who contracted HPV may start to feel the effects of a persistent infection, which can result in the development of cervical cancer. Hence ages of 31 and 65 hold a significant share of the global market.
The hospital segment accounted for a revenue share of 39.7% in the global market at the end of 2022.
Hospitals typically have specialized departments or clinics dedicated to women's health, including cervical cancer screening. These facilities ensure that the testing is conducted in a controlled and efficient manner.
Overall, hospitals offer a setting that encourages interaction between healthcare practitioners with various expertise, making it the lucrative segment of end users.
Among the primary approaches used by manufacturers to get a competitive edge in the market are pricing strategies, market strategies, technical advancements, regulatory compliance, and acquisition and distribution agreements with other businesses to expand their business.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in cervical cancer screening market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Test, Cancer, Age Group, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; Becton, Dickinson, and Company; F. Hoffmann-La Roche; Hologic, Inc.; QIAGEN; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Promega Corporation; Sysmex Inostics Inc.; Danaher (Cepheid); FUJIREBIO; Everlywell, Inc.; Sansure Biotech Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The hospital holds high revenue potential.
The United States, Japan, and Germany are advancing in healthcare.
The market is forecast to register a CAGR of 13.7% through 2033.
During 2018 to 2022, the market registered a CAGR of 7.4%.
The popularity of new advanced test technologies increases current market trends.
Explore Diagnostic Devices Insights
View Reports
Cervical Cancer Screening Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
